02 / Coverage Universe

Coverage

Company profiles and research in one searchable index.

47 companies Published research linked where available

Search

Therapeutic areaProfile typeSort

47 of 47

Stage is shown separately from the Clinaptis view. “Under review” means no current stance is published.

Acadia PharmaceuticalsConstructive

$3.44B

NUPLAZID (pimavanserin) · Parkinson's disease psychosis

Commercial

Jul 29, 2026Jul 29

Agios PharmaceuticalsNeutral

$1.90B

Mitapivat · Sickle cell disease

Under FDA review

Sep 22, 2026Sep 22

AlkermesNeutral

$7.00B

LYBALVI / Alixorexton · Schizophrenia, BP-I / narcolepsy

Commercial

Jun 12, 2026Jun 12

Amgen Inc.Neutral

$217.90B

Repatha (evolocumab) · Hypercholesterolemia

Commercial

Sep 14, 2026Sep 14

Amylyx PharmaceuticalsConstructive

$3.49B

Avexitide · Post-bariatric hypoglycemia

Phase 3

Jul 2, 2026Jul 2

Annexon, Inc.Constructive

$794M

Vonaprument (ANX007) · Geographic atrophy

Phase 3

Aug 26, 2026Aug 26

Arrowhead PharmaceuticalsConstructive

$9.07B

REDEMPLO (plozasiran) · Familial chylomicronemia

Commercial

Jun 25, 2026Jun 25

Axsome TherapeuticsCautious

$9.39B

Auvelity (dextromethorphan / bupropion) · MDD / Alzheimer’s agitation

Commercial

Jun 20, 2026Jun 20

BridgeBio PharmaConstructive

$13.15B

Attruby (acoramidis) · ATTR-CM

Commercial

—

BiohavenUnder review

$1.94B

Opakalim (BHV-7000) · Focal epilepsy

Phase 2/3

—

BiogenPositive

$32.49B

Leqembi (lecanemab) · Early Alzheimer's disease; preclinical AD expansion

Commercial

Jul 16, 2026Jul 16

BioMarin PharmaceuticalNeutral

$11.07B

Voxzogo (vosoritide) · Achondroplasia

Commercial

—

Celldex TherapeuticsCautious

$2.49B

Barzolvolimab (CDX-0159) · Chronic Spontaneous Urticaria

Phase 3

Aug 15, 2026Aug 15

Corbus Pharmaceuticals Holdings, Inc.Constructive

$119M

CRB-913 · Obesity

Phase 2

Aug 30, 2026Aug 30

CytokineticsNeutral

$9.12B

MYQORZO (aficamten) · Obstructive HCM

Commercial

—

Definium TherapeuticsConstructive

$5.03B

DT120 ODT · Generalized anxiety disorder

Phase 3

Sep 5, 2026Sep 5

Dyne TherapeuticsNeutral

$2.84B

DYNE-251 · DMD, exon 51 amenable

Under FDA review

Oct 8, 2026Oct 8

ExelixisCautious

$14.47B

Cabometyx (cabozantinib) · RCC, HCC, NET / solid tumors

Commercial

—

Structure TherapeuticsConstructive

$1.97B

Aleniglipron (GSBR-1290) · Obesity and overweight

Phase 3

Aug 8, 2026Aug 8

Harmony BiosciencesNeutral

$2.31B

WAKIX (pitolisant) · Narcolepsy / hypersomnia

Commercial

—

Ionis PharmaceuticalsNeutral

$7.24B

TRYNGOLZA (olezarsen) · FCS / severe triglyceridemia

Commercial

Jul 16, 2026Jul 16

Jazz PharmaceuticalsCautious

$15.30B

Modeyso (dordaviprone) · H3 K27M diffuse midline glioma

Commercial

—

Kodiak SciencesNeutral

$5.94B

Zenkuda (tarcocimab tedromer) · Wet age-related macular degeneration

Phase 3

Aug 22, 2026Aug 22

Kura OncologyConstructive

$947M

KOMZIFTI (ziftomenib) · R/R NPM1-mutated AML in adults

Commercial

—

Eli LillyCautious

$1.08T

Mounjaro / Zepbound (tirzepatide) · Type 2 diabetes / obesity

Commercial

Sep 30, 2026Sep 30

Madrigal PharmaceuticalsNegative

$11.54B

Rezdiffra (resmetirom) · Noncirrhotic MASH, F2–F3

Commercial

Jun 3, 2026Jun 3

MapLight TherapeuticsNeutral

$546M

ML-007C-MA · Schizophrenia

Phase 3

Jul 9, 2026Jul 9

Neurocrine BiosciencesNeutral

$14.55B

Ingrezza (valbenazine) · TD / Huntington’s chorea

Commercial

—

Intellia TherapeuticsConstructive

$1.72B

Lonvoguran ziclumeran (lonvo-z; NTLA-2002) · Hereditary angioedema

Phase 3

—

Novo Nordisk A/SConstructive

$128.18B

Wegovy (semaglutide) 2.4 mg injectable · Obesity / cardiometabolic

Commercial

Jun 8, 2026Jun 8

Praxis Precision MedicinesCautious

$8.25B

Relutrigine · Broad DEE

Phase 3

Sep 29, 2026Sep 29

PTC TherapeuticsNeutral

$5.30B

Evrysdi (risdiplam) · Spinal muscular atrophy

Commercial

—

uniQureConstructive

$1.63B

Ifezuntirgene inilparvovec (AMT-130) · Huntington’s disease

Filed

Jun 30, 2026Jun 30

Relmada TherapeuticsUnder review

$384M

NDV-01 · Non-muscle invasive bladder cancer

Phase 2/3

—

Revolution MedicinesNeutral

$44.29B

RASONQUE / daraxonrasib · Metastatic pancreatic cancer

Commercial

Jun 1, 2026Jun 1

Rhythm Pharmaceuticals, Inc.Cautious

$6.39B

IMCIVREE (setmelanotide) · Acquired hypothalamic obesity

Commercial

Sep 19, 2026Sep 19

Syndax PharmaceuticalsConstructive

$1.57B

Revuforj (revumenib) · NPM1m / KMT2Ar acute leukemia

Commercial

—

Sarepta TherapeuticsCautious

$1.85B

ELEVIDYS · Ambulatory DMD, age 4+

Commercial

—

Scholar RockCautious

$5.70B

Apitegromab · Spinal muscular atrophy

Commercial

Jul 20, 2026Jul 20

Stoke TherapeuticsConstructive

$1.65B

Zorevunersen (STK-001) · Dravet syndrome

Phase 3

—

Teva Pharmaceutical Industries Ltd.Neutral

$45.32B

AUSTEDO / AUSTEDO XR · TD / Huntington’s chorea

Commercial

—

TG TherapeuticsCautious

$8.31B

Briumvi (ublituximab) IV · Relapsing multiple sclerosis

Commercial

—

Travere TherapeuticsConstructive

$5.37B

FILSPARI (sparsentan) · IgA nephropathy

Commercial

—

Vera TherapeuticsCautious

$2.19B

TRUTAKNA (atacicept-vymj) · Primary IgA nephropathy

Commercial

Jun 28, 2026Jun 28

Viking TherapeuticsCautious

$3.81B

VK2735 (subcutaneous) · Obesity

Phase 3

Sep 23, 2026Sep 23

Xenon PharmaceuticalsConstructive

$3.68B

Azetukalner · Focal seizures

Filed

—

Zealand PharmaConstructive

$2.74B

Petrelintide · Chronic weight management

Phase 3

—

Market data current as of October 2, 2026. Source: Google Finance.